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ABSTRACT 
Estrogens are a class of hormones that are demonstrated to be neuroprotective. The levels of 
estrogen in the body decline during menopause which can cause a variety of symptoms. 
Hormone replacement therapy (HRT) is a treatment option for menopause, however, it has been 
demonstrated to have adverse side effects. Of the treatment options for adverse side effects of 
HRT, Selective estrogen Down-regulators do not appear to have an agonist effects on estrogen 
receptors while Selective estrogen receptor Modulators do. The aim of this study was to 
determine the role that estrogen receptors play in the survival of astrocytes when placed under 
stress with epinephrine as well as when treated with a well-known SERD. The results of this 
experiment indicated that treatment with estrogens did not offer any neuroprotection. Future 
studies should focus on differing concentrations of variables and different exposure times to 
further evaluate the mechanisms of estrogen signaling. 
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Menopause is a natural life transition for women that are between 40 and 50 years of age. 
Women normally experience symptoms including, but not limited to, hot flashes, mood changes, 
and decreased sex drive. These symptoms are due to a decrease in the production of the female 
hormones estrogen and progesterone (De Souza and Ogava, 2014). Estrogens are a class of 
hormones that are found naturally in both sexes and have various physiological effects. Aside 
from their reproductive function, estrogens help regulate the metabolism of lipids and 
carbohydrates as well as influence the cardiovascular and neurological systems (Vrtacnik et. al., 
2014). The treatment that is often used to help alleviate the symptoms of menopause is hormone 
replacement therapy (HRT). However, studies have been conducted that demonstrate that HRT 
can have adverse side effects such as increased risk of stroke, breast cancer and cardiovascular 
disease (Schmidt et ah, 2006). The preferred treatment option is oral conjugated equine estrogens 
(CEE) as they are cost effective and convenient. However, despite this benefit, they have the 
above mentioned side effects (Schmidt, 2006). Due to the adverse side effects of CEE, it is 
recommended to minimize estrogen replacement by administering the lowest effective dose with 
the shortest possible duration. The central nervous system acclimates to the decrease in estrogen 
levels over time in many postmenopausal women, causing a natural decline of menopause 
symptoms (Schmidt et ah, 2006). 
The most dominant and potent estrogen is 17 beta-estradiol, although there are small 
amounts of 17 alpha-estradiol, estrone and estriol present in the body as well (Bjomstrom and 
Sjoberg, 2005). The reproductive functions of estrogens are to promote the expression of primary 
and secondary sex characteristics in females. They also have effects on male physiology as well 
as cardiovascular and central nervous system health (Vrtacnik et. al, 2014). Due to their role in 
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the central nervous system, the decline in estrogen levels during menopause can cause women to 
experience symptoms of memory loss, depression, and possibly more serious disorders such as 
Alzheimer’s disease (De Marinis et al., 2011). Studies have shown that estrogens have a 
protective action on the brain and, with early intervention, estrogen therapy can help decrease the 
vulnerability to neurodegenerative diseases (Wang et al., 2006). Grimes and Hughes (2015) 
conducted an in vitro study to determine the neuroprotective effects of 17-beta estradiol, and two 
CEEs; equilin and equilenin at varying concentrations against oxidative stress on astrocyte cells. 
Their results indicated that CEEs offer some degree of protection against oxidative stress for 
short tenn exposure. However, when exposed to a longer period of oxidative stress, CEEs and 
17-beta estradiol were not as effective in preventing cell death (Grimes and Hughes, 2015). 
Hormone replacement therapy has been implemented as a treatment option for the 
declining levels of estrogens during menopause. This treatment option has been shown to help 
alleviate several symptoms of menopause including hot flashes, vaginal dryness and a decreased 
risk of osteoporosis (Souza and Ogava, 2014). Oral conjugated equine estrogens (CEEs), such as 
Premarin (Pfizer), contain several different estrogens from the urine of pregnant mares including 
hormones that are not naturally producing in humans (Zhao and Brinton, 2006). The composition 
is made up of sulfate esters of classical estrogens and ring-beta unsaturated estrogens that include 
equilin and equilenin. While the goal of HRT is help increase estrogen levels in the body and has 
several benefits, studies have shown that CEEs can have negative side effects as well, which 
include an increased risk of ovarian, breast and endometrial cancer (Souza and Ogava, 2014). 
There are notable differences between endogenous human estrogens, particularly 
estradiol, and the components of CEEs. Estradiol primarily regulates its effects through estrogen 
receptor (ER) alpha, while some of the estrogens found in CEEs are mediated by ER beta 
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(Bhavnani and Stanczyk, 2014). Estrogen receptors have different effects on the body and are 
expressed at different levels in specific tissues in the body. ER alpha is primarily found in the 
uterus, breast tissue, adipocytes and kidneys, while ER beta is prevalent in the colon, lungs and 
bladder. Both receptors are found at varying levels in testes, ovaries and the brain (Vrtacnik et. 
al, 2014). 
Astrocytes are the predominant form of glial cells in the brain and spinal cord. They are 
supportive cells for neurons and are involved in the formation of the blood brain barrier as well 
as synaptic transmission between neurons. Another important function that they have in the 
central nervous system is regulation of hormones, particularly in female reproduction (Micevych, 
et al., 2010). Ovulation occurs in females when there is a spike in luteinizing hormone (LEI), 
which is triggered by gonadotropin releasing hormone (GnRH) from the hypothalamus. LEI is 
directly influenced by estradiol, which has a positive feedback on both LEI and GnREI. Neurons 
involved in the release of GnRH do not have estrogen receptors; estradiol must first stimulate 
astrocytes to control the expression of GnRH (Micevych et al., 2010). 
Along with regulation of ovulation, the astrocyte-estrogen relationship is involved in 
neuroprotection against dementia and other neurodegenerative diseases. Studies have shown that 
estrogen mediates glutamate uptake. Glutamate is a neurotransmitter involved in cognition but at 
high levels can be toxic to neurons, which is the reason that declining estrogen levels can lead to 
dementia (Liang et al. 2002). The concentration of glutamate in the cell is regulated by glutamate 
transporters that remove the neurotransmitter from the extracellular space. Estradiol has been 
shown to increase the amount of glutamate transporters on astrocytes, therefore providing 
neuroprotection and decreasing the vulnerability to neurodegenerative diseases (Lan, et al. 2014). 
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Estrogen influences neural physiology by targeting neuronal and glial cells found in the 
brain. Mechanisms of estrogen signaling include direct and indirect genomic signaling, non- 
genomic signaling and ligand-independent signaling. Estrogen signaling occurs through two 
different nuclear estrogen receptors, ER alpha and ER beta (Henderson, 2007). The classic model 
of estrogen signaling is direct genomic signaling, involving the nuclear receptors ER-alpha and 
ER-beta (Vrtacnik et. al, 2014). In direct genomic signaling, estrogens first bind to a ligand 
receptor in the nucleus, which causes these receptors to polymerize and then bind to estrogen 
response elements (EREs) that are found within the target genes. Target genes that are affected 
include insulin-like growth factor (IGF), collagenase and cyclin D1. Estrogens target genes in the 
central nervous system that are related to promoting neuronal growth and survival through 
transcription regulation (Bjomstrom and Sjoberg, 2005). Estrogen signaling can also occur 
through G protein-coupled estrogen receptor 1 (GPER1) which is located on the cell’s plasma 
membrane and controls rapid estrogen signaling (Vrtacnik et al., 2014). Estrogen binds to 
GPER1 and activates adenylate cyclase and protein kinases that have several different effects on 
the body. GPER1 is different both structurally and genetically from both nuclear estrogen 
receptors (Vrtacnik et al., 2014). 
Several studies have been conducted on drugs available for the treatment of menopause 
symptoms in women in regards to their interaction with the ER receptors, specifically ER alpha. 
A significant portion of these studies focus on the treatment of breast cancer with two therapies 
(Yeh, et al 2013). Selective estrogen receptor modulators (SERMs) are a common drugs of 
choice that can be either ER alpha agonists or antagonists, depending on the target tissue, and 
affect gene expression in various ways (Hadji, 2012). Tamoxifen has been a particularly 
successful SERM in regards to the treatment of breast cancer due to its antagonistic effects on 
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breast tissue. However, a side effect of the drug is endometrial cancer which demonstrates its 
agonist effects within uterine tissue (Hadji, 2012). The second type are Selective estrogen 
receptor Down-regulators (SERDs) which do not appear to show any agonist properties and 
down regulate ER expression by degrading the ER alpha protein (Yeh, et al 2013). The most 
common SERD is fulvestrant, which is an analog of 17 beta-estradiol that acts as a competitive 
inhibitor for the binding of 17 beta-estradiol to its receptor and consequently has a higher affinity 
for the binding site compared to tamoxifen. Unlike tamoxifen; which just affects transcription 
through the ER receptors, fulvestrant fully destroys the ER protein, leading to complete 
suppression of signaling of 17 beta-estradiol via the estrogen receptor (Yeh, et al., 2013). 
This study will aim to determine the genomic mechanism of estrogen signaling through 
ER alpha when cells are placed under stress with epinephrine and how survival is influenced by 
the addition of fulvestrant when treated with CEEs. I hypothesize that astrocytes that are placed 
under stress will show decreased survival when treated with fulvestrant and estrogen compared 
to those that do not receive the treatment due estrogen is not able exert any neuroprotective 
effects once the receptor is degraded. Also, I predict that astrocytes that are treated with 
equilenin will show decreased viability in comparison to those treated with 17 beta-estradiol. 
Methods 
Cells 
The cells used in this study were human cultured astrocytes (132INI, Sigma Aldrich). 
Astrocytes were prepared in media and stored at 37° C and 5% CO2 in an incubator and the 
media was changed every 2 to 3 days. Media consisted of 10 mL of Dulbecco's Modified Eagle's 
Medium, 10% fetal bovine serum, 2mM L-glutamine and 1% antibiotic and antimycotic in T-75 
flasks. When cells became confluent, media was removed and a 10 mL solution of trypsin-EDTA 
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was added to the flask to remove the adherent cells from the surface. The flask was placed back 
in the incubator for 15 minutes. After the cells had dispersed, the contents of the flask were 
placed in tube along with 10 mL of media and centrifuged at 3000 rpm for 3 minutes. The 
supernatant was discarded and the cell pellet was re-suspended in 5 mL of media. 200 pL of cell- 
suspension with a concentration of 1 x 106 cells/mL was added to each respective well (Grimes 
and Hughes, 2015). To determine the concentration of cells, a hemocytometer was used to 
manually count cells. A solution made of 10 pL of prepared astrocytes with an equal amount of 
trypan blue solution was mixed in a well. The addition of the trypan blue solution showed 
presence of live and dead cells. Using a micropipette, 10 pL of the trypan blue -cell suspension 
mixture was pipetted onto the hemocytometer with a coverslip applied. Using an inverted 
microscope, both dead and live cells were counted (cells/mL). The number of cells counted was 
then used to calculate the amount of cell suspension and media needed to dilute to a final 
concentration of 1 x 106 cells/mL. The total amount of media that was to be used was obtained 
by multiplying the number of wells used by the volume of media in each well and then adding an 
extra 200 pL to ensure that there would be enough media available. (12 wells x 200 pL = 2400 
pL + 200 = 2600 pL used). Once the volume of cell suspension was calculated, this was 
subtracted from the total amount of media used to give the final amount of media that would be 
added with the cell suspension. The solution of cell suspension and media was added to the 
respective wells at 200 pL/well and treatments began the next day. The formula for the 
calculation is shown here: 
(cells\ 
1 x 10A6 , ) (Total media used in pL) 
^volume ui ceu suspension in pcj =--------- 
(# of cells counted) 
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Treatment of Astrocytes 
In order to test the hypotheses about the effects of estrogens on astrocytes, cells were treated 
with a fixed concentration of 1 pM equilenin or 17-beta estradiol (Grimes and Hughes, 2015). 
Cells were either oxidatively stressed using 1 pM epinephrine for 1.5 hours or kept unstressed. 
The concentration of epinephrine was obtained from preliminary work conducted by a graduate 
student at Columbus State University who examined astrocyte exposure to varying levels of 
epinephrine. There were also wells with no estrogen treatment to use as controls. 20 pL of 
Fulvestrant (1 pM) was added one hour prior to the treatment with estrogens (Jansen et al., 
2002). 20 pL of DMSO was added to wells without any fulvestrant. The astrocytes were then 
treated with 10 pL of estrogens for one hour, followed by the addition of 20 pL of epinephrine 
(10 pM) for 1.5 hours. For wells without estrogens or epinephrine, the same concentration of 
PBS was added. The media was changed after being treated with epinephrine and viability of the 
astrocytes was measured 24 hours later. Four trials were completed with the same steps listed 
above. The 96-well plate is diagrammed in Table 1. 
Table 1. 96-well plate diagram for treatments. Cells were first treated with 20 pL of fulvestrant, 
20 pL of DMSO was added to cells without fulvestrant. After 1 hour with fulvestrant treatment, 
cells were treated with 10 pL of equilenin or 17(3 estradiol, 10 uL of PBS was added to wells 
without any estrogen treatment. After 1 hour with estrogen treatment, cells were treated with 20 
pM of epinephrine for 1.5 hours. Media was changed after epinephrine treatment. Equilenin (Q) 
and 17J3 estradiol (E): 1 pM; Epinephrine (Epi): 10 pM; Fulvestrant (F): 1 uM; <-*-) and (-) 
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MTT Cell Proliferation Assay 
After treatments were complete, viability was accessed using MTT Cell Proliferation Assay 
(Sigma Aldrich). The media was removed from each well and 100 pi was added to each 
respective well as well as 2 wells to use as blanks for comparisons. 10 pi of the MTT reagent 
was then added, followed by incubation of the astrocytes for 2 hours and then 100 pi of the MTT 
solubilization solution was added to the wells. Absorbance was recorded at 570nm, with a high 
absorbance value indicating greater cell viability. 
Analysis of data 
The independent variables that were measured were treatment of estrogens and fulvestrant and if 
astrocytes are stressed or not stressed with epinephrine. To evaluate statistical significance 
between treatments, a Tukey’s post hoc test and 3-way Analysis of Variance (ANOVA) was 
conducted with a p-value < 0.05 indicating statistical significance. Four trials were completed 
with the same steps listed previously. 
Results 
The absorbance values obtained from the MTT Assay were averaged and then converted to a 
ratio with the control. There was no significant difference found for astrocytes that were treated 
with estrogens (17-beta estradiol and equilenin) and those that were treated without estrogens 
(0.89 +/- 0.63 for 17-beta estradiol and 1.2 +/- 0.72 for equilenin, p=0.540) and the two estrogens 
did not differ significantly from each other (p= .559) or the treatment without estrogen (p=0.651 
for equilenin, p=0.988 for 17-beta estradiol). Figure 1 shows the average cell viability (+/- S.D.) 
for cells that were treated with estrogen alone, compared to the control which had no treatment. 
Cells that were treated with fulvestrant or epinephrine in addition to estrogen treatment showed 
no significant difference between those that were treated without fulvestrant or epinephrine 
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treatment and estrogen (p=0.144 for fulvestrant, p=0.634 for epinephrine). Figures 2 and 3 show 
a comparison of treatment with estrogen vs. cells treated with estrogen and epinephrine (1.4 +/- 
1.1 for equilenin and 1.8 +/- 1.2 for estradiol, Figure 2) and cells treated with estrogen and 
fulvestrant (1.3 +/- 1.4 for equilenin and 0.67 +/- 0.54 for estradiol, Figure 3). Treatment with 
fulvestrant alone showed no significant difference between cells that were left untreated with 
fulvestrant (1.2 +/- 1.1, p=0.940). There was no significant difference for cells that were treated 
with epinephrine alone compared to cells that were treated without epinephrine (0.98 +/- 0.73, 
p=0.222). Cells that were treated with fulvestrant, estrogen and epinephrine showed no 
significant difference from any other combination (2.3 +/- 2.4 for equilenin pretreatment and 
0.64 +/- 0.47 for estradiol pretreatment, p=0.759). There was no significant difference between 
cells that were left untreated with estrogens but treated with fulvestrant and epinephrine and 
those that were not treated with either (1.4 +/- 0.94, p=0.944). Figure 4 shows a collective 
comparison of all combinations of treatment. 
Since treatment with epinephrine did not show any significant effect on cell viability, the 
data were then analyzed by eliminating epinephrine as a variable to see if there was a significant 
difference between cells that were treated with fulvestrant and estrogen compared to those 
without any estrogen treatment. There was no significant difference between cells treated will 
fulvestrant alone and those treated without fulvestrant (p=0.938). Cells that were treated with 




Figure 1. Average astrocyte viability (4/- 1 S. D.) following treatment with 1 uM of estrogen 










Figure 2. Comparison of average astrocyte viability' (+■/- 1 S.D.) for cells treated with 1 pM of 
estrogen (equiienin or estradiol) with cells treated with 1 pM estrogen and 10 pM epinephrine. 







Figure 3. Comparison of average astrocyte viability (+/- 1 S.D.) for cells treated with 1 pM of 
estrogen (equilenin or estradiol) with cells treated with 1 pM estrogen and 10 pM epinephrine 
and cells treated with 1 pM estrogen and 1 uM of fulvestrant. Results were not significant. 
Treatment 
Figure 4. Comparison of average astrocyte viability (+/- 1 S.D,) for cells treated with 1 pM of 
estrogen (equilenin or estradiol) with cells treated with 1 pM estrogen and 10 jiM epinephrine, 1 
pM estrogen and 1 pM of fulvestrant and cells treated with 1 pM estrogen, 1 pM of fulvestrant 
and 10 uM of epmephrine. Results were not significant. 
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Discussion 
Treatment with fulvestrant, epinephrine, and both endogenous estrogens and CEEs showed no 
significant difference in astrocyte viability compared to the control, which received no treatment. 
Combinations of any of the treatments also showed no significant difference between each other, 
even with the eliminating of the epinephrine in analysis. In this particular study, estrogens at a 
concentration of 1 pM did not provide any benefit or harm to astrocytes at normal conditions for 
human cultured astrocytes with or without treatment of epinephrine. However, a previous study 
using a murine in vitro model conducted by Grimes and Hughes (2015) showed evidence that 
estrogens play a role in neuroprotection when oxidatively stressed with hydrogen peroxide 
(Grimes and Hughes, 2015). While this particular study provided no justification that 
epinephrine acted as a stressor on astrocytes, studies have been conducted that show that 
epinephrine and dopamine, another catecholamine, demonstrate toxic effects on neuronal cells at 
high concentrations (> 1 mM) (Noh et al 1999). The concentration used in this study (10 pM) 
may have been too low to induce any neurotoxicity. 
Fulvestrant prevents estrogen from signaling through transcriptional regulation by 
completely degrading the ER protein, which is why it is considered to be a complete antagonist 
of the estrogen receptor (Yeh et al 2013). If estrogens are neuroprotective, then it would be 
expected that when they are placed under stress, treatment with fulvestrant would show a 
decrease in cell survival as estrogens are not able to provide any neuroprotection. However, this 
hypothesis was not supported by the results of this study. This could possibly be due to a 
different signaling mechanism, in which estrogen could be acting via a second messenger system 
by utilizing a G-protein coupled receptor in astrocytes. It is also possible that exposure time was 
not adequate for the fulvestrant or the concentration was too low. 
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This study was limited in that the number of repetitions and trials were few due to time 
constraints. There was also only one fixed concentration for each independent variable which 
limited the range of data that was able to be collected. Data was limited on the effects that 
fulvestrant has on the central nervous system as most research has focused on breast cancer cell 
lines as fulvestrant is often used as a therapy for patients who have developed metastatic breast 
cancer as a result of hormone replacement therapy (Jansen et al 2002). This made it difficult to 
determine adequate dosing and exposure time for the application of the fulvestrant. It is possible 
that the fulvestrant did not have enough time to exert its effects on the ER receptor or that the 
dose was too low to have any significant effects. 
Future studies should examine differences in viability for differing concentrations of 
epinephrine, as well as looking at other catecholamines and their role in astrocyte survival. This 
study focused solely epinephrine and it would be interesting to examine if there are any 
differences between epinephrine and other catecholamine derivatives. Epinephrine did not 
appear to have any significant effect on viability which could be due a concentration that was too 
diluted or it may not have any effect on neuroglia. Few studies have focused on the neurotoxicity 
of epinephrine so it is necessary to conduct further treatments to evaluate if it can have a 
significant effect on viability at different concentrations. Also, exposure time of fulvestrant 
should be increased as well as experimenting with different concentrations to determine if either 
has an effect on astrocyte survival. Future studies could also look at measuring oxidative stress 
as well as effects of oxygen deprivation on viability. Grimes and Flughes (2015) showed that 
CEEs offer neuroprotection for short term stress with hydrogen peroxide at certain 
concentrations. While the results of this study did not provide any support for neuroprotection of 
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either endogenous estrogens or CEEs, varying concentrations and exposure time could provide 
further insight into the mechanism of estrogen receptor signaling. 
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